Search results
Congenital Adrenal Hyperplasia: Navigating a Rare, Lifelong Condition Often Diagnosed at Birth
The Tomahawk· 3 days agoClick here to view this image from .
Oppenheimer cuts Spruce Biosciences shares target, cites updated revenue forecasts By Investing.com
Investing.com· 1 day agoSpruce Biosciences recently provided financial and business updates for the first quarter of 2024....
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Benzinga· 4 days agoSAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock
Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to Buy at StockNews.com
ETF DAILY NEWS· 14 hours agoJPMorgan Chase & Co. lifted their target price on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. HC Wainwright ...
TD Asset Management Inc Purchases New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
ETF DAILY NEWS· 5 days agoTD Asset Management Inc acquired a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with ...
Spruce Biosciences, Inc. to Post Q1 2025 Earnings of ($0.29) Per Share, HC Wainwright Forecasts...
ETF DAILY NEWS· 5 days agoSpruce Biosciences, Inc. (NASDAQ:SPRB – Free Report) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Spruce Biosciences in a research ...
Seven Eight Capital LP Invests $951,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
ETF DAILY NEWS· 4 days agoSeven Eight Capital LP acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 7,215 shares ...